At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 156 enrolled
Drug / intervention
Remdesivir (RDV) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
In Brief
A Phase 2 clinical trial evaluating Remdesivir (RDV) and Placebo for COVID-19. Completed, enrolled 156 participants across 28 sites.
Detailed Summary
The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in participants with early stage coronavirus disease 2019 (COVID-19).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartSep 2020
Primary CompletionFeb 2021
Study CompletionMar 2021
TodayJul 2026
First PostedSep 4, 2020
Enrollment StartSep 14, 2020
Primary CompletionFeb 26, 2021
Study CompletionMar 22, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.8 years ago
Interventions
Remdesivir (RDV)drug
Administered as an aerosolized solution
Placebodrug
Administered as an aerosolized solution